MedTrace Logo

Exploration of Personalized Biomarkers During Neoadjuvant Radiation Therapy for Spinal and Sacral Chordoma

NCT06463262 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-10-24

No results posted yet for this study

Summary

In this study the investigators will study the effects of neoadjuvant radiation therapy (RT), in the form of either proton therapy or stereotactic body radiation therapy (SBRT), on the Circulating tumor DNA (ctDNA), radiographic changes and radiomics, and the validity of these findings will be compared using the current gold standard- pathologic findings. The purpose of this work is to explore whether the biomarkers may be used diagnostically to better understand radiographic changes following RT. The investigators hypothesize that ctDNA levels in combination with imaging biomarkers identified through radiomics will be a sensitive and specific tool for predicting histopathologic response to RT.

Conditions

  • Chordoma of Spine
  • Chordoma of Skull Base
  • Chordoma of Sacrum

Interventions

DIAGNOSTIC_TEST

ctDNA

the effects of neoadjuvant RT, in the form of either proton therapy or SBRT, on the ctDNA

Sponsors & Collaborators

  • Canon Medical Systems, USA

    collaborator INDUSTRY

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Kristin Redmond, MD, MPH · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-14
Primary Completion
2029-07-31
Completion
2031-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06463262 on ClinicalTrials.gov